Guidelines of care for atopic dermatitis

Journal of the American Academy of Dermatology

Volumn 50, Issue 3, 2004, Pages 391-404

  Hanifin, Jon M ^a   Cooper, Kevin D ^a   Ho, Vincent C ^a   Kang, Sewon ^a   Krafchik, Bernice R ^a   Margolis, David J ^a   Schachner, Lawrence A ^a   Sidbury, Robert ^a   Whitmore, Susan E ^a   Sieck, Carol K ^a   Van Voorhees, Abby S ^a   Bechtel, Mark A ^a   Elewski, Boni E ^a   Feldman, Steven R ^a   Hoffman, Cindy Francyn ^a   Kirsner, Robert S ^a   Lieblich, Lawrence M ^a   Poulin, Yves P ^a   Reed, Barbara R ^a   Robertson, Dirk B ^a   Warshaw, Erin W ^a   Smith, Daniel A ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DOXEPIN; EMOLLIENT AGENT; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOGLOBULIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; PREDNISONE; RECOMBINANT GAMMA INTERFERON; TACROLIMUS; TAR; THEOPHYLLINE; THYMOPENTIN; TRIAMCINOLONE ACETONIDE;

ATOPIC DERMATITIS; BURNING SENSATION; CATARACT; CHINESE HERB; CONTACT ALLERGY; DIET RESTRICTION; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; GROWTH RETARDATION; HUMAN; HYDRATION; HYPNOSIS; INTRAOCULAR PRESSURE ABNORMALITY; MASSAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; PUVA; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SKIN CARE; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION;

EID: 12144285759     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.08.003     Document Type: Article

References (212)

1. Goodman CS. National Information Center on Health Services Research & Health Care Technology (NICHSR) [Web site]. TA101 Introduction to health care technology assessment. January 1998. Available at: http://www.nlm.nih.gov/nichsr/ ta101/ta101_c1.htm. Accessed July 11, 2002.
2. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92:44-47.
3. Costa C, Rilliet A, Nicolet M, et al. Scoring atopic dermatitis: the simpler the better? Acta Derm Venereol 1989;69:41-45.
4. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD Index. Consensus report of the european task force on atopic dermatitis. Dermatology 1993;186:23-31.
5. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131:383-396.
6. Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996;13548:25-30.
7. Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996;135:509-515.
8. Chandra RK, Hamed A. Cumulative incidence of atopic disorders in high risk infants fed whey hydrolysate, soy, and conventional cow milk formulas. Ann Allergy 1991;67:129-132.
9. Halken S, Host A, Hansen LG, et al. Effect of an allergy prevention programme on incidence of atopic symptoms in infancy. A prospective study of 159 "high-risk" infants. Ann Allergy 1992;47:545-553.
10. Marini A, Agosti M, Motta G, et al. Effects of a dietary and environmental prevention programme on the incidence of allergic symptoms in high atopic risk infants: three years follow-up. Acta Paediatr 1996;414:1-21.
11. Odelram H, Vanto T, Jacobsen L, et al. Whey hydrolysate compared with cow's milk-based formula for weaning at about 6 months of age in high allergy-risk infants: effects on atopic disease and sensitization. Allergy 1996;51:192-195.
12. Bergmann RL, Diepgen TL, Kuss O, et al. Breastfeeding duration is a risk factor for atopic eczema. Clin Exp Allergy 2002;32:205-209.
13. Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol 1995;95:1179-1190.
14. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001;357:1076-1079.
15. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119-121.
16. Rosenfeldt V, Benfeldt E, Nielsen SD, Jeppesen DL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389-95.
17. Saarinen UM, Kajosaari T. Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years old. Lancet 1995;346:1065-69.
18. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol 1999;38:604-606.
19. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionateThe Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999;140:1114-1112.
20. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-936.
21. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
22. Holgate ST, Frew AJ. Choosing therapy for childhood asthma. N Engl J Med 1997;337:1690-1692.
23. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-955.
24. Whitmore SE. Inhaled corticosteroids and likelihood of cataract extraction. JAMA 1999;281:791-793.
25. Sambrook PN. Inhaled corticosteroids, bone density, and risk of fracture. Lancet 2000;355:1385.
26. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991;25:1166-1169.
27. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther 1997;19:710-719.
28. Maloney JM, Morman MR, Stewart DM, et al. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998;37:142-144.
29. Moshang T. Prednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitis. Cutis 2001;68:63-69.
30. Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991;24:603-607.
31. Yawalkar SJ, Schwerzmann L. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol 1991;25:1163-1166.
32. Jorizzo J, Levy M, Lucky A, et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 1995;33:74-77.
33. Aliaga A, Rodriguez M, Armijo M, et al. Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol 1996;35:131-132.
34. Wolkerstorfer A, Strobos MA, Glazenburg EJ, et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998;39:226-231.
35. Ainley-Walker PF, Patel L, David TJ. Side to side comparison of topical treatment in atopic dermatitis. Arch Dis Child 1998;79:149-152.
36. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol 1998;138:293-296.
37. Wolkerstorfer A, Visser RL, De Waard van der Spek FB, et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol 2000;143:999-1004.
38. Thomas KS, Armstrong S, Avery A, et al. Randomized controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002;324:768.
39. Cato A, Swinehart JM, Griffin EI, et al. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Int J Dermatol 2001;40:232-236.
40. Paller AS, Nimmagadda S, Schachner L, Mallory SB, Kahn T, Willis I, Eichenfield. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dematol 2003;48:569-77.
41. Yunginger JW, Calobrisi SD. Investigation of the allergenicity of a refined peanut oil-containing topical dermatologic agent in persons who are sensitive to peanuts. Cutis 2001;68:153-155.
42. Deleted in revision.
43. Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995;133:592-597.
44. Tharp MD. A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Cutis 1996;57:19-26.
45. Hanifin JT, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-537.
46. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000;355:1399-1403.
47. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-947.
48. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
49. Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol 1978;114:1165-1167.
50. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-484.
51. Turpeinen M, Mashkilleyson N, Bjorksten F, et al. Salo OP. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Derm Venereol 1988;68:331-335.
52. Lucky AW, Grote GD, Williams JL, et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997;59:151-153.
53. Matsuda K, Katsunuma T, Iikura Y, et al. Adrenocortical function in patients with severe atopic dermatitis. Ann Allergy Asthma Immunol 2000;85:35-39.
54. Tan MH, Lebwohl M, Esser AC, et al. The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol 2001;45:392-396.
55. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-393.
56. Kelly JW, Cains GD, Rallings M, Gilmore SJ. Safety and efficacy of monetasone furoate cream in the treatment of steroid responsive dermatoses. Australian J Dermatol 1994;32:85-91.
57. Stroughton RB, Wullich K. The same glucocorticoid in brand name products: does increasing the concentration result in greater topical biologic activity? Arch Dermatol 1989;125:1509-1511.
58. Shah VP, Peck CC, Skelly JP. Vasoconstriction-skin blanching-assay for glucocorticoids. Arch Dermatol 1989;125:1558-1561.
59. Stroughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987;123:1312-1314.
60. Aalto-Korte K, Turpeinen M. Bone mineral density in patients with atopic dermatitis. Br J Dermatol 1997;136:172-175.
61. Bates DW, Black DM, Cummings SR. Clinical use of bone densitometry-clinical applications. JAMA 2002;288:1898-1900.
62. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry-scientific review. JAMA 2002;288:1889-1897.
63. Fairfield KM, Fletcher RH. Vitamins for chronic disease in adults-scientific review. JAMA 2002;287:3116-3126.
64. Stevens LM, Lynn CL, Glass RM. Vitamins A to K. JAMA 2002;287:JAMA Patient Page.
65. Willett WC, Stampper MJ. What vitamins should I be taking doctor? N Engl J Med 2001;345:1819.
66. Munkvad M. A comparative trial of Clinitar versus hydrocortisone cream in the treatment of atopic eczema. Br J Dermatol 1989;121:763-766.
67. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994;31:613-616.
68. Berberian BJ, Breneman DL, Drake LA, et al. The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol 1999;38:145-148.
69. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-56.
70. Hanifin JM, Hebert AA, Mays SR, et al. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res Clin Exp 1998;59:227-233.
71. Chamlin SL, Frieden IJ, Fowler A, et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001;137:1110-1112.
72. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisEASI Evaluator Group. Exp Dermatol 2001;10:11-18.
73. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-821.
74. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-644.
75. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:547-557.
76. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
77. Sugiura H, Uehara M, Hoshino N, et al. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol 2000;136:1062-1063.
78. Soter NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44:S39-S46.
79. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001;44:S28-S38.
80. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-S64.
81. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-546.
82. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-555.
83. Alaiti S, Kang S, Fiedler VC, Ellis CM, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998;38:69-76.
84. Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-809.
85. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-787.
86. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-794.
87. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
88. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) [Website]. CDER drug approvals 1998-2002. Updated May 14, 2002. Available at: http://www-.fda.gov/cder/approval/index.htm. Accessed August 15, 2002.
89. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;143:23-30.
90. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:3-10.
91. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six month study. Dermatology 2002;205:271-277.
92. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
93. Griffiths CEM, Van Leent EJM, Gilbert M, Traulsen J, on behalf of the Cipamfylline Study Group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 12-butyrate cream for the treatment of AD. Br J Dermatol 2002;147:299-307.
94. Ewing CI, Ashcroft C, Gibbs AC, et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998;138:1022-1029.
95. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974;90:525-530.
96. Leung DYM. Role of Staphylococcus aureus in atopic dermatitis. In: Bieber T, Leung DYM, editors. New York: Marcel Dekker; 2002. p. 401-418.
97. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60.
98. Boguniewicz M, Sampson H, Leung SB, et al. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001;108:651-652.
99. Kolmer HL, Taketomi EA, Hazen KC, et al. Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis. J Allergy Clin Immunol. 1996;98:702-707.
100. Stalder JF, Fleury M, Sourisse M, et al. Comparative effects of two topical antiseptics (chlorhexidine vs KMn04) on bacterial skin flora in atopic dermatitis. Acta Derm Venereol 1992;176:132-134.
101. Breneman DL, Hanifin JM, Berge CA, et al. The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000;66:296-300.
102. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Derm 1998;119:189-98.
103. Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996;7(Suppl):S15-S22.
104. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999;135:1522-1525.
105. 1receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early treatment of the atopic child. J Allergy Clin Immunol 1999;104:433-440.
106. Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993;70:127-133.
107. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990;122:545-551.
108. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992;14:17-21.
109. La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994;73:117-122.
110. Doherty V, Sylvester DG, Kennedy CT, et al. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. BMJ 1989;298:96.
111. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy 1994;49:22-26.
112. Sloper KS, Wadsworth J, Brostoff J. Children with atopic eczema. I: Clinical response to food elimination and subsequent double-blind food challenge. Q J Med 1991;80:677-693.
113. Lever R, MacDonald C, Waugh P, et al. Randomized controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol 1998;9:13-19.
114. Mabin DC, Sykes AE, David TJ. Controlled trial of a few foods diet in severe atopic dermatitis. Arch Dis Child 1995;73:202-207.
115. Mabin DC, Sykes AE, David TJ. Nutritional content of few foods diet in atopic dermatitis. Arch Dis Child 1995;73:208-210.
116. Isolauri E, Tahvanainen A, Peltola T, et al. Breast-feeding of allergic infants. J Pediatr 1999;134:27-32.
117. Worm M, Ehlers I, Sterry W, et al. Clinical relevance of food additives in adult patients with atopic dermatitis. Clin Exp Allergy 2000;30:407-414.
118. Berth-Jones J, Graham-Brown RA. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993;341:1557-1560.
119. Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic dermatitis and asthma. Arch Dis Child 1996;75:494-497.
120. Giménez-Arnau A, Barranco C, Alberola M, et al. Effects of linoleic acid supplements on atopic dermatitis. Adv Exp Med Biol 1997;433:285-289.
121. Henz BM, Jablonska S, van de Kerkhof PC, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol 1999;140:685-688.
122. Bamford JT, Gibson RW, Renier BS. Atopic unresponsive to evening primrose oil (linoleic and y-linolenic acids). J Am Acad Dermatol 1985;13:959-965.
123. Mabin DC, Hollis S, Lockwood J, et al. Pyridoxine in atopic dermatitis. Br J Dermatol 1995;133:764-767.
124. Ewing CI, Gibbs AC, Ashcroft C, et al. Failure of oral zinc supplementation in atopic eczema. Eur J Clin Nutr 1991;45:507-510.
125. Sanda T, Yasue T, Oohashi M, et al. Effectiveness of house dustmite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol 1992;89:653-657.
126. Tan BB, Weald D, Strickland I, et al. Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347:15-18.
127. Friedmann PS, Tan BB. Mite elimination-clinical effect on eczema. Allergy 1998;53:97-100.
128. Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol 2000;143:379-384.
129. Gutgesell C, Heise S, Seubert S, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001;145:70-74.
130. Koopman LP, van Strien RT, Kerkhof M, et al. Placebo-controlled trial of house dust mite-impermeable mattress covers: effect on symptoms in early childhood. Am J Respir Crit Care Med 2002;166:307-313.
131. Holm L, Bengtsson A, Ohman S, et al. Effectiveness of occlusive bedding in the treatment of atopic dermatitis: a placebo-controlled trial of 12 months' duration. Allergy 2001;56:152-158.
132. Andersen PH, Bindslev-Jensen C, Mosbech H, et al. Skin symptoms in patients with atopic dermatitis using enzyme-containing detergents. A placebo-controlled study. Acta Derm Venereol 1998;78:60-62.
133. Kubota K, Machida I, Tamura K, et al. Treatment of refractory cases of atopic dermatitis with acidic hot-spring bathing. Acta Derm Venereol 1997;77:452-454.
134. Broberg A, Kalimo K, Lindblad B, et al. Parental education in the treatment of childhood atopic eczema. Acta Derm Venereol 1990;70:495-499.
135. Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. Br J Dermatol 2002;146:432-439.
136. Staughton R. Psychologic approach to atopic skin disease. J Am Acad Dermatol 2001;45(Suppl):S53-S54.
137. Cole WC, Roth HL, Sachs LB. Group psychotherapy as an aid in the medical treatment of eczema. J Am Acad Dermatol 1988;18:286-291.
138. de L. Horne DJ, White AE, Varigos GA. A preliminary study of psychological therapy in the management of atopic eczema. Br J Med Psychol 1989;62:241-248.
139. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995;63:624-635.
140. Jekler J, Larkö O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. Br J Dermatol 1991;125:569-572.
141. George SA, Bilsland DJ, Johnson BE, Ferguson J. Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 1993;128:49-56.
142. Grundmann-Kollmann M, Behrens S, Podda M, et al. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999;40:995-997.
143. Ogawa H, Yoshiike T. Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment. Pediatr Dermatol 1992;9:383-385.
144. Sheehan MP, Atherton DJ, Norris P, et al. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol 1993;129:431-436.
145. Morris AD, Saihan EM. Maintenance psoralen plus ultraviolet A therapy: does it have a role in the treatment of severe atopic eczema? Br J Dermatol 2002;146:705-707.
146. Collins P, Ferguson J. Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br J Dermatol 1995;133:653-655.
147. Hudson-Peacock MJ, Diffey BL, Farr PM. Narrow-band UVB phototherapy for severe atopic dermatitis. Br J Dermatol 1996;135:332.
148. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998;38:589-593.
149. von Kobyletzki G, Pieck C, Hoffmann K, et al. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol 1999;41:931-937.
150. Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000;42:254-257.
151. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. Lancet 2001;357:2012-2016.
152. Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001;45:503-507.
153. Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994;287:48-52.
154. Prinz B, Michelsen S, Pfeiffer C, et al. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999;40:577-582.
155. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000;25:559-566.
156. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-446.
157. Leroy BP, Lachapelle JM, Somville MM, et al. Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis. Dermatologica 1991;182:98-106.
158. Leroy BP, Boden G, Jacquemin MG, et al. Allergen-antibody complexes in the treatment of atopic dermatitis: preliminary results of a double-blind placebo-controlled study. Acta Derm Venereol 1992;176:129-131.
159. Leroy BP, Boden G, Lachapelle JM, et al. A novel therapy for atopic dermatitis with allergen-antibody complexes: a doubleblind, placebo-controlled study. J Am Acad Dermatol 1993;28:232-239.
160. 2 fragments of specific antibodies. Br J Dermatol 1995;132:599-603.
161. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999;83:548-552.
162. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001;12:154-158.
163. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001;44:89-93.
164. Capella GL, Frigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001;11:209-213.
165. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990;70:323-329.
166. Korstanje MJ, van de Staak WJBM. Cyclosporin maintenance therapy for severe atopic dermatitis. Acta Derm Venereol 1991;71:356-357.
167. Munro CS, Higgins EM, Marks JM, et al. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol 1991;124:43-48.
168. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-140.
169. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129:422-430.
170. Munro CS, Levell NJ, Shuster S, et al. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994;130:376-380.
171. van Joost TH, Heule F, Korstanje M, et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994;130:634-640.
172. Granlund H, Erkko P, Sinisalo M, et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995;132:106-112.
173. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996;34:1016-1021.
174. Chawla M, Ali M, Marks R. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis. Br J Dermatol 1996;135:9-14.
175. Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996;135:21-24.
176. Zonneveld IM, De Rie MA, Beljaards RC, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 1996;135:15-20.
177. Berth-Jones J, Graham-Brown RA, Marks R, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997;136:76-81.
178. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-58.
179. Bunikowski R, Staab D, Kussebi F, et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr Allergy Immunol 2001;12:216-223.
180. Hanifin JM, Schneider LC, Leung DY, et al. Recombinant interferon-gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-197.
181. Reinhold U, Kukel S, Brzoska J, et al. Systemic interferongamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993;29:58-63.
182. Musial J, Milewski M, Undas A, et al. Interferon-gamma in the treatment of atopic dermatitis: influence on T-cell activation. Allergy 1995;50:520-523.
183. γ) for atopic dermatitis. Ann Allergy Asthma Immunol 1998;80:263-268.
184. Stevens SR, Hanifin JM, Hamilton T, et al. Long-term effectiveness and safety of recombinant human interferon-gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799-804.
185. Jolles S, Sewell C, Webster D, Ryan A, et al. Adjunctive highdose intravenous immunoglobulin (HdIVIg) treatment for resistant atopic dermatitis-efficacy and effects on intracellular cytokine levels and CD4 counts. London (UK): National Institute for Medical Research, Division of Cellular Immunology; 2000. 102296/verilli.
186. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000;42:1033-1040.
187. Leung DY, Hirsch RL, Schneider L, et al. Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 1990;85:927-933.
188. Hsieh KH, Shaio MF, Liao TN. Thymopentin treatment in severe atopic dermatitis-clinical and immunological evaluations. Arch Dis Child 1992;67:1095-1102.
189. Stiller MJ, Shupack JL, Kenny C, et al. A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol 1994;30:597-602.
190. Wakim M, Alazard M, Yajima A, et al. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998;81:153-158.
191. Noh G, Lozano F. Intravenous immune globulin effects on serum-soluble CD5 levels in atopic dermatitis. Clin Exp Allergy 2001;31:1932-1938.
192. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001;26:369-375.
193. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al.
194. Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000;143:385-391.
195. Grundmann-Kollmann M, Podda M, Ochsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001;137:870-873.
196. Ruzicka T. Effect of theophylline in atopic dermatitis: a double-blind cross-over study. Arch Dermatol Res 1980;269:109-110.
197. Berth-Jones J, Graham-Brown RA. Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study. Br J Dermatol 1990;122:553-557.
198. Shupack J, Stiller M, Meola T Jr, et al. Papaverine hydrochloride in the treatment of atopic dermatitis: a double-blind, placebo-controlled crossover clinical trial to reassess safety and efficacy. Dermatologica 1991;183:21-24.
199. Keane FM, Munn SE, du Vivier AWP, et al. Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 1999;318:563-564.
200. Sheehan MP, Rustin MH, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992;340:13-17.
201. Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992;126:179-184.
202. Sheehan MP, Atherton DJ. One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 1994;130:488-493.
203. Sheehan MP, Stevens H, Ostlere LS, et al. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clin Exp Dermatol 1995;20:136-140.
204. Latchman Y, Banerjee P, Poulter LW, et al. Association of immu nological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). Int Arch Allergy Immunol 1996;109:243-249.
205. Fung AY, Look PC, Chong LY, But PP, Wong E. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol 1999;38:387-392.
206. Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol 1998;134:1388-1393.
207. Pheric-Walton L, Murray V. Toxicity of Chinese herbal remedies. Lancet 1992;340:673-674.
208. Ferguson JE, Chalmers RJG, Rowlands DJ. Reversible dilated cardiomyopathy following treatment of atopic eczema with Chinese herbal medicine. Br J Dermatol 1997;136:592-593.
209. Perharic L, Shaw D, Leon C. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet Hum Toxicol 1995;37:562-566.
210. McMenamy CJ, Katz RC, Gipson M. Treatment of eczema by EMG biofeedback and relaxation training: a multiple baseline analysis. J Behav Ther Exp Psychiatry 1988;19:221-227.
211. Stewart AC, Thomas SE. Hypnotherapy as a treatment for atopic dermatitis in adults and children. Br J Dermatol 1995;132:778-783.
212. Schachner L, Field T, Hernandez-Reif M, et al. Atopic dermatitis symptoms decreased in children following massage therapy. Pediatr Dermatol 1998;15:390-395.